SAN DIEGO–Molecular Response announced today that it has launched a clinically validated BRAF test to detect the V600E mutation in both melanoma and colorectal tumors.

The announcement comes on the heels of the news that the FDA has approved Roche’s Zelboraf™ (vemurafenib) for melanoma patients harboring the BRAF V600E mutation.

“We’re excited to expand our precision medicine offerings with the BRAF V600E test,” said Richard Scuderi, MD, PhD, Medical Director at Molecular Response. “This subpopulation of melanoma patients is going to benefit greatly from vemurafenib, and Molecular Response will play a key part in helping those patients know if they are likely to benefit.”

Molecular Response’s BRAF V600E mutation test is a PCR-based test that has been validated as a CLIA Laboratory Developed Test and demonstrated superiority in terms of sensitivity and sample acceptance criteria to other clinical laboratories offering BRAF V600E mutation testing.

“The test is very robust and has fantastic sensitivity,” said Thomas Broudy, PhD, Chief Scientific Officer at Molecular Response. “In the end, that translates to one important fact — we’ll be able to tell more patients if their tumor harbors the mutation, and they can use that information with their doctor to make better therapeutic decisions, especially now that vemurafenib is approved.”

For additional online ordering information visit: www.molecularresponse.com/braf

To reach Molecular Response Client Services, call 858-622-2900 or 888-361-2826.

Zelboraf is a trademark filed by Genentech, Inc.

About Molecular Response

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs. Our results reduce risk and cost of drug development and allow for the most informed decisions with best chance of success to advance therapeutic programs.